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INTRODUCTION  
 Topical drug delivery is well-known for the treatment of local skin disorders, 
but the use of the skin as a route for systemic drug delivery is a more recent 
development. Very few Transdermal products have been approved to date, largely 
because of the complexities involved in achieving a consistent delivery rate. There are 
many variables that influence the absorption of drugs across the skin and into the 
general circulation, including the biological properties of the skin, chemical properties 
of the drug, and the interactions between skin and drug delivery system. Systematic 
studies have led to complications of permeability data for a range of drugs through skin, 
both stratum corneum and dermis. These studies reflect the large variability and 
slowness of the process for most drugs. Consequently, only a few drug candidates are 
currently available for transdermal drug delivery. There are efforts to improve the 
process which involve conditioning the skin1. 
 In recent years transdermal route now ranks with oral treatment as the most 
successful innovative research area in drug delivery, with around 40% of the drug 
delivery candidate product under clinical evaluation related to transdermal or dermal 
system. The transdermal drug delivery systems (TDDS) have been designed as an 
alternative route for systemic drug delivery. The systemic drug administration though 
skin holds several advantages such as maintenance constant drug level in blood, 
decrease of side effects, and improvement of bio availability by circumvention of 
hepatic first pass metabolism and increase patient compliance. Now a day’s skin 
considered as a safe port for drug administration, to provide continuous drug release 
into systemic circulation. Recently, bio polymers used in the fabrication of transdermal 
films has received much attention due to their excellent biocompatibility and bio 
degradation2. One of the most promising techniques for enhancement for transdermal 
permeation of drugs is transdermal patches. Sodium alginate (SA) is a natural polymer 
is very promising and has been widely exploited in pharmaceutical industry, because of 
its tailor‐made to suit the demands of applications3. Locust bean gum (LBG) is a 
hydrophilic polymer, had been limited for use in thickening, suspending, and 
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emulsifying water based systems. It is gaining appreciation for the fabrication of 
pharmaceuticals with uniform drug release characteristics4. Drug release property of 
matrices is preceded by polymer hydration and the rate of drug release from polymer 
carrier can be tailor‐made by selecting a suitable polymer‐blends composition and drug 
concentration5. The effect of hydrophilic plasticizers such as glycerin on 
physicochemical properties on SA/LBG film was evaluated. Ketoprofen (KF) belongs 
to the group of substituted 2‐phenylproprionic acids which has analgesic, 
anti‐inflammatory and antipyretic effects. KF exerts the majority of its analgesic actions 
through inhibition of the synthesis of prostaglandins by inhibiting the enzyme 
cyclooxygenase (COX)6. KF had the best topical penetration ability when compared to 
ketorlac, indomethacin and other studies have found that topical KF was effective for 
the treatment of well localized soft tissue injury, joint pain, in reducing muscle soreness 
after repetitive muscle contraction. The importance of KF in the therapeutic field has 
stimulated the development of topical dosage forms to improve its percutaneous 
absorption through the application site. Moreover topical dosage forms could provide 
relatively consistent drug levels for prolonged periods and avoid gastric irritation, as 
well as the other typical side effects of oral NSAID administration7. 
 Penetration depends on ability of drug to penetrate the stratum corneum, enter 
the systemic circulation and to achieve the therapeutic effect. There has been increased 
interest during recent years in the use of chemical enhancer that could modify drug 
permeation through skin. Many of the chemical enhancers may be harmful, especially in 
chronic applications, many of them were irritant in nature. It is desirable to develop 
topical delivery systems that do not require the use of chemical enhancers to facilitate 
drug permeation through skin. In the present study we made an attempt by using 
menthol as a penetration enhancer. Because menthol is considered to have good 
permeation enhancing agent by acting as a lipid disrupting agent that increases the 
fluidity of stratum corneum lipid by increasing the formation of capillary channels8. 
Ttransdermal films with varied ratios nonirritating and pharmaceutically acceptable 
biopolymers SA and LBG combination containing the drug KF with permeation 
INTRODUCTION 
 
3 
 
enhancer (menthol). The prepared films were compared with the marketed conventional 
gel. Furthermore, films was evaluated for anti‐inflammatory activity on carrageenan 
induced rat paw edema model. The purpose was to provide the delivery of drug at a 
controlled rate across intact skin to achieve a therapeutically effective drug Transdermal 
Drug Delivery Systems are defined as self-contained, discrete dosage forms which, 
when applied to the intact skin, deliver the drugs, through the skin, at controlled rate to 
the systemic circulation. Transdermal Drug Delivery Systems are designed to support 
the passage of drug substances from the surface of the skin through its various layers 
and into the systemic circulation. In response to this new idea several transdermal drug 
delivery systems have recently been developed, aiming to achieve the objective of 
systemic medication through topical application to the intact skin surface 
1.1. Advantages of Transdermal Drug Delivery System9 
 Avoid GI absorption problems 
 Avoid first-pass effect, thus minimizing drug input 
 Oral administration to be avoided or is contraindicated 
  Drugs with narrow therapeutic index can be delivered 
 Better control of drug levels for potent drug is possible 
 Increased patience compliance 
 Self medication is possible 
 Drugs with short t1/2 values are utilized. 
1.2 Disadvantages of Transdermal drug delivery system: 
 Neither practical nor affordable for drugs with large doses 
 When drug or formulation is skin sensitizing or irritating 
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 Extensive metabolism in skin 
 Large molecular size preventing diffusion through skin 
1.3 Problems associated with transdermal drug delivery system 10: 
 Limited drug permeability of the skin 
 Pharmacokinetic and pharmacodynamic restrictions 
 Usable for low drug doses only 
 Possibility of irritation and hypersensitivity reactions 
 Adhesion problems 
 Skin permeability variation 
 High cost of treatment 
1.4 Transdermal drug absorption markedly alters drug kinetics and depends on a 
several parameters including the following-  
  Medicament application site  
  Thickness and integrity of the stratum cornea epidermis.  
  Size of the molecule that is to be administered.  
  Permeability of the membrane for the transdermal drug delivery.  
  Hydration state of skin.  
  pH of the drug.  
  Drug metabolism by skin flora.  
  Lipid solubility.  
  Drug depot in skin.  
 Blood flow alteration in the skin by additives and body temperature  
The toxic effect of the drug and problem in limiting drug uptake are major 
considerable potential for transdermal delivery systems, especially in children because 
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skin thickness and blood flow in the skin usually vary with age. The increased blood 
supply in the skin along with thinner skin has significant effects on the 
pharmacokinetics of transdermal delivery for children. In some situations this may be 
an advantageous, while in others systemic toxicity may occur. This was observed after 
using scopolamine patches that are used to prevent motion sickness, a eutectic mixture 
of local anesthetics (EMLA) cream used to minimize the pain, corticosteroid cream 
applied for its local effect on skin maladies. Episodes of systemic toxic effects, 
including some fatalities in children have been documented with each of these, often 
secondary to accidental absorption through mucous membranes5. 
1.5 Basic components of Transdermal drug delivery systems11 
The basic components of Transdermal devices include 
A. Baking membrane 
B. Polymer matrix or matrices that regulate the release of the drug 
C. Drug substance  
D. Penetration enhancer 
E. Plasticizer 
F. Adhesive 
G. Release liner 
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FIG NO:1 Components of Transdermal Drug Delivery System 
A. Baking membrane 
The backing layer must be impermeable to the drugs and enhancers, if used, and as 
result, it is usually impermeable to water vapor i.e. occlusive. 
B. Polymer matrix  
Polymers are the backbone of a Transdermal drug delivery system. The polymers play a 
major role in TDDS of drugs. The release of drug to the skin is controlled by drug free 
film known as rate controlling membrane. 
 Molecular weight, glass transition temperature and chemical functionality of the 
polymer should allow proper diffusion and release of specific drug. 
 It should be chemically compatible with drug and other components of the 
system, such as penetration enhancers. 
 It should be stable, non-reactive with the drug, easy manufactured and fabricated 
into the desired product. 
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 The polymer and its degradation products must be non-toxic. 
 They also should provide consistent, effective delivery of a drug throughout the 
products intended shelf-life or delivery period. 
 The polymers should be inexpensive. 
The polymers used in TDDS include, 
(i) Natural Polymers:  
Cellulose derivatives, gelatin, shellac, waxes, proteins, gums, natural rubber starch etc. 
(ii) Synthetic Elastomers:   
Polybutadiene, polysiloxane, silicone rubber, acrylonitrile, butyl rubber, 
styrenebutadiene rubber, and neoprene etc. 
(iii) Synthetic Polymers: 
 Polyvinyl alcohol, Polyvinyl chloride, Polyethylene, Polypropylene, Polyacrylate, 
Polymide, Polyurea, Polyvinylpyrrolidone, Polymethylmethacrylate, etc. 
C. Drug substance 
The transdermal route of administration cannot be employed for a large number of 
drugs. Candidate feasibility can be deduced rationally at an early stage in development 
provided certain criteria are examined. The following are some of the desirable 
properties of drug suitable for transdermal delivery.  
The properties of drug suitable for TDDS formulation are12: 
The drug should be potent. The daily systemic dose should be ≤ 20 mg. 
 The drug should have less molecular weight i.e., < 500 - 1000 Daltons. 
 Lipophilicity- the log kp of the drug should be in the range 1-3 
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 The drug should have low melting point < 200° C 
 Hydrogen bonding groups should be < 2 
 The drug should not induce a skin irritation or allergic response. 
 The drug should not stimulate an immune reaction in the skin. 
 The half-life (t1/2) of the drug should be short. 
 The drugs which degrade in GIT or inactivated by first pass effect. 
D. Penetration enhancer 13 
Agents, which reversibly alter the barrier properties of the stratum corneum. They aid in 
the systemic delivery of drugs by allowing the drug to penetrate more rapidly to viable 
tissues are been called “penetration enhancers”. 
(i) The properties of an ideal penetration enhancer are: 
 It should be pharmacologically inert. 
 It should be non-toxic, non irritating and non allergenic. 
 Following removal of the enhancer, the stratum corneum should immediately 
and fully recover its normal barrier property. 
 The barrier should decrease in one direction only and efflux of endogenous 
material should not occur. 
 Inexpensive and cosmetically acceptable. 
(ii) Classification of penetration enhancers 
a. Terpenes (essential oils) 
E.g. Menthol, 1, 8 cineole, carvone, limonene and nerodilol etc. 
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b. Pyrrolidones 
c. Azone (1-dodecylazacycloheptan-2-one) 
d. Fatty acids and esters 
e. Sulfoxides and similar compounds 
f. Alcohols, glycols and glycerides 
g. Miscellaneous enhancers 
i. Cyclodextrin complexes 
ii. Lipid synthesis inhibitors 
iii. Enzymes 
E. Plasticizers14 
 An important method of varying membrane properties is to add a plasticizer to 
reduce the stiffness of the polymer backbone and thereby increase drug diffusion rate 
from the device. Plasticizers are used to modify the characteristics of many polymers. 
The plasticizers increase polymer chain flexibility, so that matrices with higher 
plasticizer loading normally give a higher release rate than those with lower plasticizer 
content. In the selection of plasticizer as with the polymer itself, care must be taken to 
select a material that is acceptable for use in medical applications and it is clearly 
advantageous to choose one that has already been in pharmaceutical device. Examples 
are butyl benzyl phthalate, trioctyl phosphate, dioctyl phthalate, glycerol, polyethylene 
glycol (PEG) and polypropylene glycol. 
F. Release liner 
 During storage the films is covered by a protective liner that is removed and 
discarded before the application of the film to the skin. Since the liner is in intimate 
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contact with TDDS, the liner should be chemically inert. It is therefore regarded as a 
part of the primary packaging material rather than a apart of the dosage form delivering 
the active principle. However, because the liner is in intimate contact with the delivery 
system, it should comply with specific requirements regarding the chemical inertness 
and permeation to the drug, penetration enhancer, and water. In case cross linking is 
induced between the adhesive and the release liner, the force required to remove the 
liner will be unacceptably high. 
1.5 TYPES OF TRANSDERMAL FILMS15 
Several technologies have been successfully developed to provide rate control over the 
release and skin permeation of drugs. These technologies can be classified into four 
basic approaches. 
A. Polymer membrane permeation-controlled TDD systems 
 1n this system the drug reservoir is sandwiched between a drug impermeable 
backing laminate and a rate controlling polymer membrane. The drug molecules are 
permitted to release only the rate controlling polymeric membrane. The rate of drug 
release from these TDD systems can be tailored can by varying the composition of the 
drug reservoir formulation and the permeability coefficient and thickness of the rate 
controlling membrane. Several TDD system have been successfully developed from this 
technology e.g , Transderm-nitro 
B. Polymer matrix diffusion-controlled TDD systems. 
 In this approach the drug reservoir is formed by homogeneously dispersing the 
drug solids in a hydrophilic or lipophilic polymer matrix and the medicated polymer 
formed is then molded into medicated disks with a defined surface area and controlled 
thickness. This drug reservoir containing polymer disk is than mounted in to an 
occlusive base plate in a compartment fabricated from a drug impermeable plastic 
backing. Instead of coating the adhesive polymer directly on the surface of the 
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medicated disk, in this system the adhesive polymer is applied along the circumference 
of the films to form a strip of adhesive rim surrounding the medicated disks. This type 
of TDDS is exemplified by the development of the,. Nitro-Dur system 
 Alternatively the polymer matrix dispersing type TDD system can be fabricated 
by directly dispersing the drug in a pressure sensitive adhesive polymer, e.g., 
polyacrylate, and then coating the drug dispersed adhesive polymer by solvent casting 
or hot melt on to a flat sheet of a drug impermeable backing laminate to form a single 
layer of drug reservoir . this yields a thinner and/or smaller TDD films. e.g Nito- 
glycerin-releasing TDDS, Manitran , Nitro Dur-II 
           
FIG NO: 2 Cross sectional view of Polymer matrix diffusion-controlled 
TDD systems. 
C. Drug reservoir gradient controlled TDD system 
 To overcome the non-zero order drug release profiles, polymer matrix drug 
dispersion type TDD system can be modified to have the drug loading level varied in an 
incremental manner, forming a gradient of drug reservoir along with the diffusional 
path across the multi-laminate adhesive layer. E.g Deponit 
D. Micro-reservoir dissolution-controlled TDD system 
 This type of drug delivery system can be considered as a hybrid of the reservoir 
–and matrix dispersion –type drug delivery system. In this approach the drug reservoir 
INTRODUCTION 
 
12 
 
is formed by first suspending the drug solids in an aqueous solution, of water- miscible 
drug solublizer, e.g.,  polyethylene glycol, and then homogenously dispersing the drug 
suspension, with controlled aqueous solubility in a lipophilic polymer, by high-shear 
mechanical force, to form thousand of unleachable microscopic drug reservoir. This 
thermodynamically unstable dispersion is quickly stabilized by immediately cross-
linking the polymer chains in situ, which produces a medicated polymer disk with a 
constant surface area and a fixed thickness. A TDD system is then produced by 
mounting the medicated disk at the center of an adhesive pad. e.g., Nitro Disc  
1.6 THE SKIN SITE FOR TRANSDERMAL DRUG 
ADMINISTRATION 
Anatomy and Physiology of Skin 
The skin is a large organ responsible for maintaining homeostasis through 
temperature, regulation, protection of underlying tissues, retardation of water loss, 
housing sensory receptors, synthesizing certain chemicals, and excreting wastes. The 
skin consists of an outer epidermis and a dermis, connected to underlying tissue by the 
subcutaneous layer (hypodermis). The epidermis is made up of stratified squamous 
epithelium and lacks blood vessels. It contains melanocytes and is well nourished with 
dermal blood vessels. The epidermis is important because it protects against water loss, 
mechanical injury, chemicals, and microorganisms. The dermis binds the epidermis to 
underlying tissues. The dermis consists of connective tissue with collagen and elastic 
fibers within a gel-like ground substance. Dermal blood vessels carry nutrients to upper 
layers of skin and help to regulate temperature. The dermis also contains nerve fibers, 
sensory fibers, hair follicles, sebaceous glands, and sweat glands. The subcutaneous 
layer (hypodermis) is composed of loose connective tissue and insulating adipose tissue. 
It binds the skin to underlying organs and contains the blood vessels that supply the 
skin. The accessory organs of the skin include hair follicles, sebaceous glands, nails and 
sweat glands. 
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The skin of an average body covers a surface area of approximately 2 sq. meters 
and receives about one third of the blood circulating through the body. The permeability 
barrier in the skin consists of three distinct layers in series. Epidermis, Dermis, 
Subcutaneous tissue 
Epidermis 
 The outermost layer of the skin is composed of stratified squamous epithelial 
cells Microscopically epidermis shows two main parts one is stratum corneum and the 
other is stratum germinativum. 
 The cells in the stratum corneum are physiologically inactive keratin filled cells 
that are roughly pentagonal plates of 0.5 μm thick and 30-40 μm across. Filling the 
intercellular space between these cells are bi layer structural lipids. The structures of 
these lipids have proved to be important to the moisture retaining ability of stratum 
corneum. The stratum corneum is responsible for the barrier function of skin. It also 
behaves as the primary to percutaneous absorption. 
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FIG NO: 3 SKIN 
Dermis 
 It is made up of a network of robust collagen fibers of fairly uniform thickness 
with regularly spaced cross striations. This network responsible for the elastic properties 
of the skin. Beneath the epidermis, the fibrous tissue opens out and merges with the fat 
containing subcutaneous tissue. The upper portion of the dermis is formed into the 
ridges projecting into the epidermis, which contains blood vessels and nerve ending. 
Only nerve fibers reach into the germinativam zone of the epidermis. 
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Subcutaneous fat tissue 
 This is a sheet of fat containing areolar tissue, known as the superficial fascia 
attaching the dermis to underling structures. This composite structure is pierced at 
various places by two types of potential diffusion shunts. These skin appendages 
however, actually occupy only 0.1% of the total human skin surface. This route of 
percutaneous absorption however, provides a very limited contribution to the overall 
kinetic profile of transdermal permeation. Therefore, the transdermal permeation of 
most neutral molecules at a steady state can, thus, be considered as a process of passive 
diffusion through the intact stratum corneum in the inter follicular region. Thus the skin 
serves as the point of administration for systemically active drugs. 
 The drug applied topically is distributed following absorption, first into the 
systemic circulation and then transported to target tissues. 
1.7. Factors Affecting Transdermal Permeability16 
Physicochemical properties of the peneterants 
a) Partition coefficient 
b) pH conditions 
c) Penetrant concentration 
Physicochemical properties of drug delivery systems 
a) Release characteristics 
b) Composition of drug delivery system 
Physiological and pathological conditions of skin 
a) Reservoir effect of horny layer 
b) Lipid film 
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c) Skin hydration 
d) Skin temperature 
e) Regional variation 
f) Pathological injuries to skin 
g) Cutaneous drug metabolism 
B. Kinetics of Transdermal permeation 
Transdermal permeation of a drug involves the following steps 
1) Sorption by stratum corneum 
2) Penetration of drug through viable epidermis 
3) Uptake of drug by the capillary network in the dermal papillary layer 
 
DISEASES THAT CAN BE TREATED BY TRANSDERMAL DRUG 
DELIVERY SYSTEMS 
 Skin Disorders 
 Fungus infections of Nails 
 Hair Loss 
 Cardiovascular Disorders 
 Hypertension 
 Anticoagulants 
 Chronic Obstructive Pulmonary Disease 
INTRODUCTION 
 
17 
 
 Neurological and Psychiatric Disorders 
 Parkinson’s Disease 
 Depression 
 Alzheimer’s Disease 
 Musculoskeletal Disorders 
 Osteoporosis 
 Osteoarthritis 
 Hormonal Disorders 
 Transdermal Insulin Delivery in Diabetes 
 Erectile Dysfunction 
 Menopause 
 Cancer 
 Anticancer Drugs and Vaccines 
 Pain 
 NSAIDs 
 Smoking Cessation 
 Transdermal Nicotine Replacement 
 Vaccination 
 HIV/AIDS 
 Influenza Vaccine 
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 Contraception 
 Female/Male Contraception 
VARIOUS METHODS FOR PREPARATION TDDS: 
a. Asymmetric TPX membrane method17:  
 A prototype patch can be fabricated for this a heat sealable polyester film (type 
1009, 3m) with a concave of 1cm diameter will be used as the backing membrane. 
Drug sample is dispensed into the concave membrane, covered by a TPX {poly(4-
methyl-1-pentene)}asymmetric membrane, and sealed by an adhesive. 
[(Asymmetric TPX membrane preparation): These are fabricated by using the 
dry/wet inversion process. TPX is dissolved in a mixture of solvent (cyclohexane) 
and nonsolvent additives at 60°c to form a polymer solution. The polymer solution 
is kept at 40°C for 24 hrs and cast on a glass plate to a pre-determined thickness 
with a gardner knife. After that the casting film is evaporated at 50°C for 30 sec, 
then the glass plate is to be immersed immediately in coagulation bath [maintained 
the temperature at 25°C]. After 10 minutes of immersion, the membrane can be 
removed, air dry in a circulation oven at 50°C for 12 hrs]. 
b. Circular teflon mould method18: 
 Solutions containing polymers in various ratios are used in an organic solvent. 
Calculated amount of drug is dissolved in half the quantity of same organic solvent. 
Enhancers in different concentrations are dissolved in the other half of the organic 
solvent and then added. Di-N-butylphthalate is added as a plasticizer into drug 
polymer solution. The total contents are to be stirred for 12 hrs and then poured into 
a circular teflon mould. The moulds are to be placed on a leveled surface and 
covered with inverted funnel to control solvent vaporization in a laminar flow hood 
model with an air speed of 0.5 m/s. The solvent is allowed to evaporate for 24 hrs. 
The dried films are to be stored for another 24 hrs at 25±0.5°C in a desiccators 
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containing silica gel before evaluation to eliminate aging effects. The type films are 
to be evaluated within one week of their preparation. 
c. Mercury substrate method19: 
 In this method drug is dissolved in polymer solution along with plasticizer. The 
above solution is to be stirred for 10- 15 minutes to produce a homogenous 
dispersion and poured in to a leveled mercury surface, covered with inverted funnel 
to control solvent evaporation. 
d. By using “IPM membranes” method20: 
 In this method drug is dispersed in a mixture of water and propylene glycol 
containing carbomer 940 polymer and stirred for 12 hrs in magnetic stirrer. The 
dispersion is to be neutralized and made viscous by the addition of triethanolamine. 
Buffer pH 7.4 can be used in order to obtain solution gel, if the drug solubility in 
aqueous solution is very poor. The formed gel will be incorporated in the IPM 
membrane. 
e. By using “EVAC membranes” method21:  
 In order to prepare the target transdermal therapeutic system, 1% carbopol 
reservoir gel, polyethelene (PE), ethylene vinyl acetate copolymer (EVAC) 
membranes can be used as rate control membranes. If the drug is not soluble in 
water, propylene glycol is used for the preparation of gel. Drug is dissolved in 
propylene glycol, carbopol resin will be added to the above solution and neutralized 
by using 5% w/w sodium hydroxide solution. The drug (in gel form) is placed on a 
sheet of backing layer covering the specified area. A rate controlling membrane will 
be placed over the gel and the edges will be sealed by heat to obtain a leak proof 
device. 
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f. Aluminium backed adhesive film method22: 
 Transdermal drug delivery system may produce unstable matrices if the loading 
dose is greater than 10 mg. Aluminium backed adhesive film method is a suitable 
one. For preparation of same, chloroform is choice of solvent, because most of the 
drugs as well as adhesive are soluble in chloroform. The drug is dissolved in 
chloroform and adhesive material will be added to the drug solution and dissolved. 
A custammade aluminium former is lined with aluminium foil and the ends blanked 
off with tightly fitting cork blocks. 
g. Preparation of TDDS by using Proliposomes23,24: 
 The proliposomes are prepared by carrier method using film deposition 
technique. From the earlier reference drug and lecithin in the ratio of 0.1:2.0 can be 
used as an optimized one. The proliposomes are prepared by taking 5mg of mannitol 
powder in a 100 ml round bottom flask which is kept at 60-70°c temperature and the 
flask is rotated at 80-90 rpm and dried the mannitol at vacuum for 30 minutes. After 
drying, the temperature of the water bath is adjusted to 20-30°C. Drug and lecithin 
are dissolved in a suitable organic solvent mixture, a 0.5ml aliquot of the organic 
solution is introduced into the round bottomed flask at 37°C, after complete drying 
second aliquots (0.5ml) of the solution is to be added. After the last loading, the 
flask containing proliposomes are connected in a lyophilizer and subsequently drug 
loaded mannitol powders (proliposomes) are placed in a desiccator over night and 
then sieved through 100 mesh. The collected powder is transferred into a glass 
bottle and stored at the freeze temperature until characterization. 
h. By using free film method25: 
 Free film of cellulose acetate is prepared by casting on mercury surface. A 
polymer solution 2% w/w is to be prepared by using chloroform. Plasticizers are to 
be incorporated at a concentration of 40% w/w of polymer weight. Five ml of 
polymer solution was poured in a glass ring which is placed over the mercury 
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surface in a glass petri dish. The rate of evaporation of the solvent is controlled by 
placing an inverted funnel over the petri dish. The film formation is noted by 
observing the mercury surface after complete evaporation of the solvent. The dry 
film will be separated out and stored between the sheets of wax paper in a 
desiccators until use. Free films of different thickness can be prepared by changing 
the volume of the polymer solution. 
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AIM 
 The main aim of the present study is to Formulate and Evaluate the Transdermal 
Drug Delivery System of Ketoprofen.  
OBJECTIVE 
 The main objective of the study is to effectively increase the Transdermal drug 
permeation and diffusion of the drug, Ketoprofen using suitable polymer, plasticizer, 
and permeation enhancer to avoid the skin irritation. 
The broad objectives of the present study is to, 
1. To select suitable polymers for Ketoprofen Transdermal films. 
2. To formulate Ketoprofen Transdermal films to ensure the control release of the skin. 
3. To evaluate physicochemical properties for the prepared formulation. 
4. To carry out in vitro diffusion studies. 
5. To carry out permeability of Ketoprofen Transdermal films through albino rat skin. 
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A.R.Mullaicharam. et. al27 have developed Flurbiprofen trandermal patches were 
formulated by using Carboxy methyl cellulose and hydroxyl propyl methyl cellulose of 
different concentrations  and evaluate for in vitro drug release behaviour. The study 
shows that hydroxy propyl methyl cellulose release was more when compared to 
carboxy methyl cellulose. 
Das. et.al28 have investigated the effects of polymeric composition, drug content and 
plasticizers on the permeation of Trazodone hydrochloride across the mouse epidermis 
in the development of TDDS and demonstrated the potential of the fabricated 
pseudolatex transdermal films for sustained release of trazodone hydrochloride. The 
concentration of triethylcitrate in the films markedly affected the skin permeation 
properties of Trazodone hydrochloride. 
R.V. Kulkarni. et.al29 have taken up to prepare and evaluate Eudergit RS100 films as 
rate controlling membrane for transdermal use and to study the various plasticizers 
effect on the permeability and mechanical properties. The investigation reveals that 
films plasticized with PEG showed higher permeability to verapamil hydrochloride. The 
permeability of the drug was decreased as the concentration of dibutyl phthalate was 
increased. Whereas increase in the concentration of Polyethylene glycol enhanced the 
permeability of the films. 
V.V. Dhavse. et.al30 have prepared ointment, creams, and gel bases containing 3%w/w 
of  Ketoprofen and evaluate for pH, drug content, rheological properties and in vitro 
drug release rate through cellophane membrane .The order of the in vitro release was 
found to be Carbapol 940gel base >polyethylene glycol ointment base >modified 
vanishing cream base >Canadian formulary cream base >modified hydrophilic base > 
beller’s ointment base >oleaginous ointment base. 
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Saxena. M. et.al31 have formulated the transdermal patches of metoclopramide 
hydrochloride by using polyvinylalcohol and polyvinylpyrrolidone for the treatment of 
nausea and vomiting. The formulation showed burst release of the drug in initial hours 
and there after drug was released slowly up to 12 h. The drug release mechanism from 
the patches was found to be diffusion dominated. 
Dey. B. K. et. al 32, have carried out to study the effect of different proportion of ethyl 
cellulose and polyvinyl pyrrolidone, a hydrophobic and hydrophilic polymer on the 
permeation profile of the drug across the rat abdomen for the development of a 
reproducible transdermal therapeutic system of propranolol hydrochloride. The study 
was demonstrated the potential of the fabricated matrix films for prolonged release of 
propranolol hydrochloride. 
K.Kawathekar. et.al33, have studied Mannich bases amides of Ketoprofen been prepared 
by using different secondary amines. Then evaluated for analgesic, anti- inflammatory 
and ulcerogenic activities and quantitative structure activity relationship. 
Pophalikarr. R.N. et.al34, have studied Mutual prodrug of ketoprofen with 
glucosamine was synthesized by reacting its acid chloride with d-glucosamine, in order 
to reduce its ulcerogenic potential and improve upon its anti arthritic activity. The study 
of prodrug was found to posses excellent antiarthitic activity without any ulcerogenic 
tendency as compared to ketoprofen when screened for ulcerogenic activity by cold 
stress method of rainsford. 
Gattani. S.G. et. al 35have prepared transdermal films of Ondansetron by using 
different hydrophilic and Lipophilic polymer combination such as poly vinyl alcohol: 
poly vinyl pyrrolidone, Ethyl cellulose: PVP later the study was extended to investigate 
the plasticizers effect such as dibutyl phthalate and propylene glycol .The result shows 
that release rate followed first order kinetics, and the permeation enhancement was 
good. 
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Gattani. S.G. et.al36 have prepared Lovastatin transdermal films by casting method on 
mercury substrate. Eight formulations were prepared by using two different polymeric 
combination, Ethyl cellulose with PVP and Eudragit RL100 with Eudragit E RS 100. 
All the formulation carried 10%w/w of lovastatin and 30%w/w of dibutyl phthalate in 
chloroform solvent .The study was carried on the basis of in vitro permeation studies. 
Shankar V, et al37 explored the different suitable methods for Transdermal applications 
as the rate controlling membrane. They evaluated various physicochemical characters of 
dry free films. They studied permeability characteristics of free film by using different 
concentration of plasticizer. From this study they concluded that faster release was 
observed from ethyl cellulose patches containing glycerol as plasticizer. 
Manvi FV, etal38 studied the physicochemical properties of Transdermal film 
formulated using different polymeric combination plasticized with polyethylene glycol 
400. They studied the effect of permeation enhancers on skin permeation kinetics by 
Keshary-chein diffusion cell. The results of the study show the feasibility of 
formulating rate controlled Transdermal therapeutic system of the drug for effective 
control and prophylaxis of allergic asthma. 
Jamakandi VG, et al 39 reviewed in detail on various drugs have been invented in the 
treatment of CVS diseases in subjected to TDDS clinical risks and benefits. The study 
concludes that, the advanced state of research and plethora of patent applications field 
for Transdermal systems clearly indicate the renewed interest of pharmaceutical 
industry in the Transdermal field. 
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Sadashivaiah R, et. al40 have prepared a matrix-type Transdermal drug delivery 
systems of haloperidol lactate using different ratios of ethyl cellulose: polyvinyl 
pyrrolidone by solvent-evaporation technique and 4% hyaluronidase enzyme as 
permeation enhancer. They have carried out different physicochemical parameters and 
in vitro permeation studies. As per the permeation studies they have illustrated that 4% 
hyaluronidase enzyme was a good enhancer. It is concluded the haloperidol lactate can 
be formulated into Transdermal polymeric patches to prolong its release characteristics 
and it is best for a sustained-release one-a-day formulation. 
Xiaoping Zhan et al 41were investigated the effect of monomers ratios, membrane 
thickness and drug concentration on the membrane permeation rates. The membranes 
were characterized by FTIR, DSC, and SEM. It was found that the copolymer 
membranes could control the drug release in the Transdermal drug delivery system 
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DRUG PROFILE 
3.2.1 KETOPROFEN 42 
Structural formula 
   
 
Molecular formula 
C16H14O3 
Molecular weight 
254.29 
IUPAC Name 
2-(3-benzoylphenyl)-propionic acid 
Category 
 Anti-inflammatory Agents 
 Cyclooxygenase Inhibitors 
 Analgesics 
 Analgesics, Non-Narcotic 
 Antipyretics 
 Nonsteroidal Anti-inflammatory Agents (NSAIAs) 
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Description 
 Nonsteroidal anti-inflammatory, analgesic drug White or off-white, odorless, 
nonhygroscopic, fine to granular powder. 
Solubility 
 Freely soluble in ethyl alcohol, chloroform, acetone, and ether and soluble in 
phosphate buffer pH 7.4, but practically insoluble in water. 
Melting point 
93 – 950C. 
Mechanism of action 
  Ketoprofen is one of the most powerful inhibitors of cyclooxygenase at 
concentrations well within the range of therapeutic plasma concentrations (EC50 2 
μg/l). It produces reversible COX inhibition by competing with the substrate, 
arachidonic acid, for the active site of the enzyme. This inhibition results in a reduction 
in the tissue production of prostaglandins such as PGE2 and PGF2α. In addition to its 
effects on cyclooxygenase, ketoprofen inhibits the lipoxygenase pathway of the 
arachidonic acid cascade. Ketoprofen is also a powerful inhibitor of bradykinin, an 
important chemical mediator of pain and inflammation 
Pharmacokinetics 
  Ketoprofen is readily absorbed from the gastrointestinal tract, peak plasma 
concentration occur about 0.5 to 2h after a dose, 99% bound to plasma proteins and 
substantial concentration of drug are found in the synovial fluid. T-max-60 to 90min. 
The plasma elimination half life is 1.5 to 4h. It is metabolized mainly by conjugation 
with glucoronic acid and is excreted mainly in the urine. Food does not affect the 
bioavailability of Ketoprofen but the rate of absorption is slowed. Metabolism involves 
hydroxylation and glucuronide conjugation and elimination by first order. 
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Uses 
1. In musculoskeletal and joint disorders such as ankylosing spondylitis, osteoarthritis 
and rheumatoid arthritis. 
2. In peri-articular disorders such as bursitis and tendonitis. 
3. It is also used in dysmenorrhoea, postoperative pain. 
4. In painful and inflammatory conditions such as acute gout or soft tissue disorders and 
to reduce fever. 
Adverse effects 
1. Pain at injection site when administered intramuscularly and occasionally tissue 
damage.  
2. Hypersensitive reactions like life-threatening asthma, urticaria, and angioderma. 
3. It causes gastrointestinal side effects like dyspepsia, nausea, abdominal pain, 
diarrhea, vomiting and constipation. 
Dose 
100-200 mg in 2 to 4 divided dose in the treatment of rheumatic disorders. 
25- 50 mg every 6-8 h in the treatment of Dysmenorrhoea 
Absorption 
 Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels 
occurring within 0.5 to 2 hours. 
Protein Binding 
99% bound, primarily to albumin 
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Metabolism 
 Rapidly and extensively metabolized in the liver, primarily via conjugation to 
glucuronic acid.  
Route of elimination 
 In a 24 hour period, approximately 80% of an administered dose of ketoprofen is 
excreted in the urine, primarily as the glucuronide metabolite. 
Half life 
Conventional capsules: 1.1-4 hours 
 Extended release capsules: 5.4 hours due to delayed absorption (intrinsic 
clearance is same as conventional capsules) 
Clearance 
 Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 
mg)] 
 Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 × 200 
mg)] 
 0.08 L/kg/h 
 0.7 L/kg/h [alcoholic cirrhosis patients] 
Toxicity 
LD50=62.4 mg/kg (rat, oral). 
 Symptoms of overdose include drowsiness, vomiting and abdominal pain. 
 Side effects are usually mild and mainly involved the GI tract. Most common 
adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, 
abdominal pain, constipation and flatulence in greater than 3% of patients. 
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3.3 POLYMERS PROFILE 
3.3.1. LOCUST BEAN GUM 43 
 
 
 
 
 Locust bean gum is a galactomannan vegetable gum extracted from the seeds of 
the carob tree. It forms a food reserve for the seeds and helps to retain water under arid 
conditions. It is used as a thickener and gelling agent in food technology. It is also 
called Carob Gum or Carubin. Locust bean gum is similar to guar gum consisting of a 
(1→4)-linked β-D- mannopyranose backbone with branchedpoints from their 6-
positions linked to α-D-galactose (i.e. 1→6-linked α-D-galactopyranose). There are 
about 3.5 (2.8- 4.9) mannose residues for every galactose residue. 
 
Molecular structure 
 Locust bean gum is polydisperse, consisting of non-ionic molecules made up of 
about 2000 residues. Lower galactose substitution also decreases the stiffness (i.e. 
increases the flexibility) but increases the extensibility of the isolated chains. The 
galactose residues prevent strong chain interactions but there may be up to 10-11 
unsubstituted mannose residues in a row and junction zones may form between such 
clear areas when they consist of greater than about six residues. These nano-crystalline 
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links dissociate in hot water. If the galactose residues were perfectly randomized or 
blocked, it is likely that each molecule would have more than four such areas capable of 
acting as junction zones, thus allowing gel formation. 
 
Functionality 
 
 Locust bean gum is less water soluble and has lower viscosity than guar gum as 
it has fewer galactose branch points. It needs heating to dissolve but is soluble in hot 
water. Locust bean gum differs from guar gum in that it does form thermally-
irreversible weak gels by association of the galactose deficient regions. Being non-
ionic, locust bean gum is not affected by ionic strength or pH but will degrade at pH 
extremes at higher temperatures. 
 
Description:   White to yellowish white, nearly odorless powder. 
 
Solubility:    Soluble in hot water and insoluble in ethanol. 
 
3.3.2. GLYCEROL44 
Nonproprietary names: 
 
BP:  Glycerol 
 
Chemical names and CAS registry number: 
 
Propane-1,2,3- triol 
 
Empirical formula & molecular weight: 
 
C3H8O3 MWt: 92.09 
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Structure: 
 
 
 
 
 
Functional category: 
 
 Anti microbial preservative, emollient, humectants, plasticizer, solvent, 
sweetening agent, tonicity agent. 
 
Applications in pharmaceutical formulation and technology: 
 
In topical: Humectant, emollient. 
 
In parentrals: Solvent 
 
 IN oral solutions: Solvent, sweetening agent, antimicrobial preservative, 
viscosity increasing agent Plasticizer and in film coatings. 
 
In capsules: plasticizer. 
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Typical properties: 
 
BP: 2900C 
 
Flash point: 1760C 
 
MP: 17.80C 
 
Refractive index: =1.4746 
 
 Solubility: Slightly soluble in acetone, practically in soluble in benzene, 
chloroform and oils. Soluble in ethanol and water 
 
Density: 1.2620g/cm3 at 250C. 
 
 
Stability and storage: 
 
 Mixtures of glycerine with water, ethanol(95%) and propylene glycol are 
chemically stable. Should be stored in airtight container in a cool dry place. 
 
3.3.3. MENTHOL45 
Nonproprietary names: 
 
BP: Racementhol 
 
USP: Menthol 
 
Synonynms: 
 Hexahydrothymol; 2-isopropyl-5methyl cyclohexanol; 4-iso-propyl-1-methyl 
cyclohexane-3-ol. 
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Chemical names and CAS registry number: 
 
(±)-5-methyl-2-(1-methyl ethyl)cyclohexanol [15356-70-4] 
 
Empirical formula & molecular weight: 
 
C10H20O MWt: 156.27 
 
Structure: 
     
 
Functional category: 
Flavoring agent and therapeutic agent 
 
Applications in pharmaceutical formulation and technology: 
 
 Flavoring agent, cooling agent, skin penetrating enhancer and also used in 
perfumery, tobacco products, chewing gum and as a therapeutic agent. 
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Typical properties: 
 
BP: 2120C 
 
Flash point: 910C 
 
MP: 340C 
 
Refractive index: =1.4615 
 
Solubility: Very soluble in ethanol(95%), Chloroform, ether, fatty oils and liquid 
paraffin. Soluble in acetone and benzene, Very slightly soluble in glycerine, Practically 
in soluble in water. Specific gravity: 0.904 at 150C. 
Specific rotation(α)D20: -2 to +20(10%w/v alcoholic solution. 
 
Stability and storage: 
 
 A formulation containing menthol 1% w/w in aqueous cream have been reported 
to be stable for up to 18 months when stored at room temperature. It should be stored in 
closed container at temperature not more than 250C. 
 
3.3.5. Sodium alginate 
 
 It act as a stabilizing agent, suspending agent, disintegrant and viscosity 
increasing agent, good adhesive agent and better in situ gel forming agent. Sodium 
alginate is odorless, tasteless. Pale yellow, brown coloured powder. Alaklinity pH 
7.2.Insoluble in ethanol, ether and other organic solvents. It is hygroscopic material, 
stable at cool room temperature 
MATERIALS AND METHODS 
 
37 
 
4. MATERIALS AND METHODS 
4.1 MATERIALS 
 
4.1.1 List of chemicals and reagents 
  
Ketoprofen was a gift sample from Yarrow Chem Products, Wadala, Mumbai, India. 
 
Table 1. List of chemicals and reagents 
 
Materials 
 
Source 
 
Locust bean gum 
 
Sisco research laboratories, Mumbai. 
 
Sodium alginate 
 
SD Fine chemical Ltd, Mumbai. 
 
Glycerin 
 
SD Fine chemical Ltd, Mumbai. 
 
Menthol 
 
SD Fine chemical Ltd, Mumbai. 
 
Chloroform 
 
SD Fine chemical Ltd, Mumbai. 
 
Glycerin 
 
SD Fine chemical Ltd, Mumbai. 
 
Disodium hydrogen 
phosphate 
 
SD Fine chemical Ltd, Mumbai. 
 
Potassium dihydrogen 
phosphate 
 
SD Fine chemical Ltd, Mumbai. 
 
Sodium hydroxide 
 
SD Fine chemical Ltd, Mumbai. 
 
 
 And other chemicals and reagents were of analytical grade and were used as 
they were procured. Distilled water was used in all experiments.  
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4.1.2 List of equipments and instruments 
 
Table 2. List of equipments and instruments 
 
 
Equipments / Instruments 
 
Source/Model 
 
Digital balance 
 
Essae teraoka limited –DS 852 J 
 
Digital pH meter 
 
Elico L1120, Ahmedabad, Microtoniks, 
model M -19 
Magnetic stirrer 
 
Remi equipments, Mumbai 
 
UV visible spectrophotometer 
 
Systronics 2201, Ahmedabad. 
 
Screw gauge 
 
Micro Co., Mumbai 
 
Hot air oven 
 
Techno scientific products, Bangalore. 
 
Tensile strength testing machine 
 
Hounse field universal testing 
machine,U.K. 
 
Franz diffusion cell 
 
Orchid scientific, Nashik. 
 
SEM 
 
JOEL JSM-T330A Scanning 
Microscope 
 
FTIR Spectrophotometer 
 
Perkin Elmer, Germany. 
 
Plethysmograph 
 
MKM, Chennai. 
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4.2 METHODS 
 
4.2.1 PREFORMULATION STUDIES 
 
 Preformulation may be defined as the stage of formulation development during 
which the physical pharmacist characterizes the physicochemical properties of the drug 
substance which are considered important in the formulation of a stable, effective and 
safe dosage form. During this evaluation, possible interactions with various inert 
ingredients intended for use in the final dosage form is also considered. In the present 
work, Preformulation studies such as solubility, determination of partition- coefficient, 
development of calibration curve, compatibility studies, and differential scanning 
calorimetry were carried out. 
 
A. Determination of Melting Point 
  
 Melting point of drug sample was performed by using Thieles tube method. A 
fine powder of Ketoprofen was filled in a capillary tube, previously sealed at one end 
and the capillary tube was tied to the bottom of the thermometer. The thermometer and 
capillary tube were immersed in to the liquid paraffin taken in the tube. Bottom of the 
tube was heated gently by means of burner. When the sample starts to melt the reading 
was recorded. 
 
B. Solubility studies48 
 The solubility was done by adding the solute in small incremental amounts to 
the fixed volume of solvents, after each addition, the system was vigorously shaken and 
examined visually for the undissolved solute particles. When some amount of the solute 
remains undissolved, the total solubility amount added upto the point served as a good 
and rapid estimate of solubility. 
 
C. Determination of partition co-efficient 49 
 
 The partition co-efficient study was performed using n-octanol as oil phase and 
phosphate buffer pH 7.4 as aqueous phase. The two phases were mixed in an equal 
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quantity and were saturated with each other on a mechanical water bath shaker at 320C 
for 24h. The saturated phases were separated by centrifugation at 2000 rpm on a Remi 
Centrifuge. Standard plots of drug were prepared from both the phosphate buffer and 
octanol. Equal volumes (10ml each) of the two phases were taken in triplicate in conical 
flask and to each 100mg of weighed amount of drug were added. The flasks were 
shaken at 320C for 6h to achieve a complete partitioning at 100rpm. The two phases 
were separated by centrifugation at 100rpm for 5min and they were then analyzed for 
respective drug contents. The partition co-efficient of drug Ko/w was calculated using 
the following formula. 
 
Ko/w =                                       Concentration in Octanol 
---------------------------------------------------------------------------- 
Concentration in phosphate buffer pH 7.4 
 
 
D. Development of Calibration Curve for Ketoprofen ( max) 50 
  
 A stock solution of Ketoprofen was prepared by dissolving 100mg of drug in 
100ml of phosphate buffer of pH 7.4. From this 10ml was taken and diluted to 100ml. 
From this 5, 10, 15, 20, 25 dilutions were prepared using phosphate buffer of pH 
7.4. The λ max of the drug was determined using UV-visible spectrophotometer. The 
absorption maximum of 260nm was selected and at this wavelength, the absorbance of 
all the other solutions was measured against a blank. The concentration ranges and 
absorbance data were reported in Table 4 Calibration graph was plotted using the data 
and presented in the Figure 5.1 
 
E. FTIR study 51 
 
 FT-IR spectroscopy study was carried to assess the compatibility between 
Ketoprofen and polymer locust bean gum, sodium alginate. The pure drug and drug 
with excipients were separately scanned. The pellets were prepared on potassium 
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bromide press. Both the spectra were compared for confirmation of peaks. The 
ketoprofen spectra and spectra data were shown in the Figure 5.2 and Table 5.  
 
F. Differential Scanning Calorimetry (DSC) 52 
 
 The dynamic DSC studies were carried out on pure drug and drug loaded films, 
the obtained thermo grams are presented in Figure 5.3. The data obtained from the DSC 
scans for the drug Ketoprofen and Ketoprofen loaded films are given in terms of onset 
of melt (To), melting points (Tm) and completion of melt (Tc). The amount of energy 
consumed for melting or the area under the endothermic peak of DSC curve of the pure 
drug and drug loaded films also presented in figure 5.3. 
 
4.2.2 FORMULATION AND EVALUATION OF TRANSDERMAL FILMS 
 
 In the present study, drug loaded matrix type transdermal films of Ketoprofen 
were prepared by molding and solvent casting method. A mould of 5cm length and 5cm 
width with a total area of 25cm2 was fabricated. 
 
A. Preparation of drug-loaded transdermal films 
 The Transdermal films were prepared by using solvent casting technique. The 
bottom of the mold was wrapped with aluminum foil which was used as backing 
membrane. Drug containing films were prepared by solution casting method. In brief, 
the required amounts of a mixture of LBG (Table 1) were weighed and prepared 
polymeric solution using quantity sufficient water, kept aside for 2h after stirring. 
Accurately weighed KF (2.5 mg/mm2) and menthol (3% w/w) was dissolved in ethanol 
(6mL) by stirring for 10 min. The above mixture mixed with different concentrations of 
glycerin (1–5% w/w) and prepared polymeric solutions for 30 min. Finally mixed soft 
mass was poured on to cleaned specially designed glass molds with the plastic 
transparent sheet and kept in a vacuum drier until to get the dried membrane. The cast 
polymer films with different formulations were then peeled off covered with aluminum 
foils and stored in a desicator until further study.  
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Table 3. Formulation chart of Ketoprofen transdermal films 
 
Formulation 
   code 
 
Ketoprofen 
   (%) 
 
Locust 
bean 
gum 
   (%) 
 
Sodium 
alginate 
  (%) 
 
Glycerin 
  (%) 
 
Menthol 
 (%) 
 
F1 2.5 4.0 92.0 0.5 1.0 
F2 2.5 25.5 70.0 1.0 2.0 
F3 2.5 40.5 52.0 2.0 3.0 
F4 2.5 30.5 60.0 3.0 4.0 
F5 2.5 10.5 80.0 3.5 4.5 
F6 2.5 1.5 87.0 4.0 5.0 
 
B. Evaluation of transdermal films 53 
 
 The prepared films were evaluated for its uniformity of weight, uniformity of 
film thickness, tensile strength, percentage elongation, folding endurance, percentage 
moisture absorption, percentage moisture loss, drug content, scanning electron 
microscopy, drug diffusion study, primary skin irritation test and anti-inflammatory 
activity. 
 
a. Uniformity of weight 54 
  
 Weight uniformity was done by weighing three different films of the individual 
batch and the average weight was calculated. Care was taken that the individual weight 
should not deviate significantly from the average weight of the three. The tests were 
performed on films, which were dried at 400C for 3h prior to testing. The data of 
uniformity of weight is shown in Table 7. 
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b. Uniformity of film thickness 55 
 
The thickness of the films was measured at different points using screw gauge. The 
average of three readings of each film at different area were measured and presented in 
the Table 8. 
 
c. Tensile strength 56 
 
 Tensile strength of the films was determined using Hounse field universal 
testing machine. It consisted of two loaded grips, the upper one was movable and the 
lower one was fixed. The test films of specific size (5х1cm2) was fixed between these 
load grips and force was gradually applied till the films broke. The tensile strength of 
the films was taken directly from the dial reading in Newtons. The data is shown in the 
Table 9. 
 
Tensile load at break 
Tensile strength =                           ------------------------------------- 
Cross sectional area 
 
d. Percentage elongation of the films 57 
 
 Percentage elongation of films is the ratio of increased length to its original 
length. It gives information of how much a specimen can elongate before it breaks. It is 
carried out by Hounse field universal testing machine. The percentage elongation at 
break point is measured on scale and the data of the percentage elongation is presented 
in the Table 9. 
 
Maximum length recorded at break – Original length 
%Elongation=                    --------------------------------------------------              x100 
Original length 
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FIG 4 (A) Transdermal films between upper and lower jaw of tensile strength machine 
(B) Original and maximum length of films at break 
 
e. Folding endurance 58 
 
 The folding endurance was measured manually for the prepared films. A strip of 
film 2x2cm was cut evenly and repeatedly folded at the same place till it broke. The 
number of times the film could be folded at the same place without breaking gave the 
exact value of folding endurance.Table10. 
 
f. Percentage moisture absorption 59 
 
 The moisture absorption studies of various films were studied at 80% relative 
humidity (RH). Films of 1cm2 of all the batches were selected. The films were weighed 
accurately and placed in a desiccator containing 100ml of fused aluminum chloride, 
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which maintains 80% of RH. After 3days, the films were taken out and weighed. The 
percentage moisture absorption was calculated using the formula.Table11 
Final weight – Initial weight 
% moisture absorption =        --------------------------------------------------              x100 
Initial weight 
 
 
g. Percentage moisture Loss 60 
 
 Films of 1cm2 of all the batches were selected. The films were weighed 
accurately and placed in a desiccator containing anhydrous calcium chloride. After 
3days, the films were taken out and weighed. The percentage moisture loss was 
calculated using the formula Table 11. 
Initial weight – Final weight 
%moisture loss =--------------------------------------------------              x100 
Initial weight 
 
 
h. Drug content 61 
 
 A formulated film having 1cm2 area was cut into small pieces and weighed 
separately. The films were transferred into a 100ml volumetric flask and 100ml of 
phosphate buffer solution (pH 7.4) was added. The medium was stirred with magnetic 
stirrer for 12h. The contents were filtered using Whatmann filter paper. The filtrate was 
analyzed at 260nm spectrophotometrically for drug content against the reference 
solution containing only placebo films. Table 12. 
 
i. Scanning electron microscopy 
 
 SEM studies are carried using JOEL JSM-T330A Scanning Electron 
Microscope. The external morphology of the formulation F3 was analyzed using a 
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scanning electron microscope to determine the drug distribution in the film and the 
SEM photos presented in Figure 5.4. 
 
J. stability of the transdermal films and prepared kf gel62 
 
 Formulation F3(2.5cm2)and conventional gel were subjected for stability studies 
at 250C/60%RH, 300C/65%RH,400C/75%RH for 90 days and the above formulations 
were evaluated for drug content periodically Table.13. 
 
K. In vitro Drug Diffusion Study 63 
 
 Drug diffusion studies were carried out in an open glass diffusion tube. A 
specimen dimension of films (2.5 cm2) was fixed to the hydrated cellophane membrane 
at one end of the open glass tube and placed in the receptor compartment containing 
buffer solution. The assembly was placed on a magnetic stirrer and stirred at 100 rpm. 
The temperature of the system was maintained at 37°C ± 1°C. A known amount of 
receptor medium (buffer) was withdrawn at regular intervals of time and sink condition 
was maintained by replacing equal volume of fresh saline. The drug concentration 
samples were measured spectrophotometrically at 260nm against blank.  
Table 14-20 
 
l. In vitro skin permeation studies 
 In vitro skin permeation studies were performed on a Franz diffusion cell with 
an effective diffusion area of 2.5 cm2 and 16 ml of receiver chamber capacity using rat 
abdominal skin. The animal study protocol was reviewed and approved by the Animal 
Ethics Committee at the Department of Pharmaceutics, MMU College of Pharmacy, 
Bangalore, Male albino rats weighing 128‐130 g were used to excise full thickness skin. 
Rats were anaesthetized by ether and then hair of abdominal skin was removed by using 
electric clipper. Special care was taken while removing hairs, not to destroy the stratum 
corneum. The cleaned skin was washed with distilled water and stored in the deep 
freezer at –21oC until further use. The skin was brought to room temperature and 
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mounted between the donor and receiver compartment of the Franz diffusion cell, 
where the stratum corneum side faced the donor compartment and the dermal side faced 
the receiver compartment. Initially the donor compartment was empty and the receiver 
chamber was filled with ethanolic phosphate‐buffered saline (PBS) pH 7.4 (30:70% 
v/v). The receiver fluid was stirred with a magnetic rotor at a speed of 300 rpm, to 
maintain the hydro dynamics of receiver fluid and the temperature maintained at 320C ± 
10C. All the ethanolic PBS was replaced every 30 minutes to stabilize the skin. It was 
found that the receiver fluid showed negligible absorbance after 5 hours and beyond, 
indicating complete stabilization of the skin. After complete stabilization of the skin, 
2.5 cm2 of the optimized film was placed. In to each donor compartment and sealed 
with paraffin film to provide occlusive conditions. Samples (0.5mL) were withdrawn at 
regular intervals (0.5, 1, 2, 3, 4, 5, 6, 7, 8 hours), filtered through a0.45‐membrane filter. 
The volume of release media was maintained by adding equal volume of fresh media 
after every sampling, Concentration of the KF in the sample was measured by m.  
 
Anti-inflammatory activity 64  
 The Anti inflammatory test was carried out on male albino rats weighing 128 
to130 g. The animals were kept under standard laboratory conditions, with temperature 
of 250C ± 10C and relative humidity of 60% ± 5%. The animals were housed in cages, 
5 per cage, with free access to a standard laboratory diet. The anti-inflammatory activity 
of KF from film formulation F3 was evaluated by the carrageenan induced hind paw 
edema method in albino rats and compared with conventional gel. The transdermal film 
was applied to the shaved abdominal skin of male rats. Just before administration of 
transdermal film, 1% carrageenan saline solution (0.1 ml) was injected into each hind 
paw of rats. The thickness of paw edema induced by carrageenan was measured by 
using a standard screw gauge during 8 h after application of KF transdermal film. 
Permeation data analysis 
 Results are given mean ± standard deviation (S.D).The cumulative amount of 
drug permeated through the skin (mg/cm2) was plotted as a function of time (t) for each 
formulation. Drug flux (permeation rate) at steady state (Jss) was calculated by dividing 
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the slope of the linear portion of the graph by the area of the diffusion cell. The 
permeability coefficient (Kp) was calculated by dividing Jss by the initial concentration 
of the drug in the donor cell (Co) 
Kp = Jss / Co…….1 
Enhancement ratio (Er) was calculated by dividing the flux of the respective 
formulation by the flux of the control formulation: 
Er = Jss of formulation / Jss of control……..2 
 The results were analyzed statistically using Student’s t 
test and significance was determined at 95% confident limit (P < 0.05). 
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5. RESULTS 
5.1 PREFORMULATION STUDIES 
 The  drug and the compatiability of the other excipients used in the formulation. 
The results of the various Preformulation characterizations are given below. 
A. Determination of Melting Point 
 Melting point of Ketoprofen was found to be 93.5oC. 
B. Solubility studies51 
 Ketoprofen is freely soluble in phosphate buffer pH 7.4, ethyl alcohol, methyl 
alcohol, chloroform, acetone, dichloro methane, and ether insoluble in water. 
C. Determination of partition co-efficient 
 The partition co-efficient studies were performed in triplicate. The value of 
partition co-efficient (P) value was experimentally found to be 0.840. The results 
obtained also indicate that the drug possesses sufficient lipophilicity, which fulfill the 
requirements of formulating the selected drug into a transdermal film. The biphasic 
nature of drug mimics the biphasic nature of skin, thus ensuring easy penetration 
through the skin. 
D. Development of Calibration Curve for Ketoprofen ( λmax) 
 The absorption maximum (λmax) is determined as 260nm. The concentration 
ranges and data are reported in Table 4. Calibration curve of Ketoprofen was plotted 
using this data and shown in the Figure5.1. 
 
 
 
 
RESULTS & DISCUSSION 
 
50 
 
Table 4. Calibration curve for Ketoprofen in pH 7.4 phosphate buffer 
Sl. 
No. 
 
Concentration 
(in µg/ml) 
 
Absorbance 
Peak Area± S.D Mean* 
 
R2 Value 
 
1. 0 0 0.9998 
2. 5 0.1540±0.0016 
3. 10 0.3097±0.0022 
4. 15 0.4504±0.0021 
5. 20 0.6113±.0103 
6. 25 0.7561±0.0038 
 
*Standard deviation, n = 3 
      
Figure5 Calibration curve of Ketoprofen in pH 7.4 phosphate buffer 
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E. FT-IR study 
 FT-IR study was employed to ascertain the compatibility of the drug ketoprofen 
with locust bean gum and sodium alginate. Both the spectra were compared for 
confirmation of common peaks. Specific peaks of pure drug and formulation showed no 
significant variation in height, intensity and positions of peaks. This proved that drug 
and excipients were compatible. There is no interaction between drug and polymer. The 
FT-IR spectra and data of ketoprofen drug and ketoprofen films are shown in the figure 
5.2 and table 5. 
Figure 6 FTIR spectra of ketoprofen and Ketoprofen films 
 
Table 5. FTIR spectra data of Ketoprofen and Ketoprofen films 
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Assignment Band position 
pure drug 
(cm-1) 
Band position 
of formulation 
( cm-1) 
C - H stretching of CH3 
group(asymmetric) masked 
by O-H stretching 
2974-2932 
 
2979-2936 
 
C - H stretching of CH3 
group(symmetric) masked 
by O-H stretching 
2882 
 
2878 
 
C = O stretching of acid 1696 1696 
C = O stretching of ketone 1654 1649 
C = C stretching of aromatic 
ring 
1593 1597 
C - H deformation of CH3 
group 
(asymmetrical) 
1441 
 
1444 
C - H deformation of CH3 
group 
(symmetrical) 
1372 
 
1369 
 
C - H deformation of 
aromatic ring 
867-691 829 – 634 
 
 From the FTIR studies, the characteristic absorption bands for important 
functional group of pure drug, empty films and drug-loaded films were identified and 
presented in Figure 5.2. IR spectra at 2979,2936cm-1 (C-H stretching of CH3 group 
(asymmetric) masked by O-H stretching), 2878cm-1 (C-H stretching of CH3 group 
(symmetric) masked by O-H stretching), 1696cm-1(C=O stretching of acid),1597cm-1 
C=C stretching of aromatic ring, 1444cm-1 (C-H deformation of CH3 
group(asymmetrical)), 1369cm-1 (C-H deformation of CH3 group- symmetrical) and 
829 - 634cm-1 C-H deformation of aromatic ring. FTIR spectra showed that the 
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characteristics bands of ketoprofen were not altered after successful drug loading 
without any change in their position, indicating no chemical interactions between the 
drug and used polymers. Compared the IR spectra and interpretation of this region in 
our spectra agrees with their conclusions52. 
F. Differential Scanning Calorimetry (DSC) 
 To understand the compatible state of the drug, DSC studies were carried out on 
pure drug and drug loaded films, the thermo grams data obtained are shown in Figure 
5.3. Ketoprofen exhibits a sharp endothermic peak at 93.250C. It was observed that 
presence of the endothermic peak at 93.360C in the drug loaded films indicated, that the 
drug is distributed in the films without any degradation and compatible with LBG/SA. 
Compared the DSC data and interpretation of this region in our data agrees with their 
conclusions as shown in Table 6. 
Figure7 DSC thermogram of Ketoprofen and Ketoprofen films 
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Table 6. DSC thermogram data of Ketoprofen and Ketoprofen films 
Formulation To (0C) Tm (0C) Tc (0C) 
Ketoprofen drug 92.82 93.25 95.12 
Ketoprofen film 
(F3) 
92.69 95.36 95.61 
 
5.2 Evaluation of Transdermal films 
 Seven film formulations of films were prepared using solution casting method 
and dried. Films consist of glycerin as a plasticizer and menthol as permeation 
enhancer. Drug loaded films were light yellow opaque in colour. All surface of the film 
was smooth, with elegant appearance, good Physical properties. Flatness of the films 
was observed better when the amount of SA > 50% in the formulated films, might be 
SA having α‐ L‐glucoronic acid, which is interact with LBG produces good flatness to 
the films. Thus these formulations can maintain a smooth and uniform surface when 
applied on skin.53   
 The drug loaded films were formulated using drug, polymer (LBG/SA), 
Glycerin used as plasticizer and different concentrations of menthol used as permeation 
enhancer. The prepared films were evaluated for its uniformity of weight, uniformity of 
film thickness, tensile strength, percentage elongation, folding endurance, percentage 
moisture absorption, percentage moisture loss, drug content, scanning electron 
microscope, in vitro drug diffusion study, primary skin irritation test and anti- 
inflammatory activity. 
Mechanical properties 
 Thickness of the prepared films was in the range of 0.13 to 0.17 mm is shown in 
Table 8. Thickness, tensile strength and % elongation of the films increasing by 
increased ratio of LBG and plasticizer in the films. Added glycerin alters the physical 
and mechanical properties by enhancing the mobility of polymers chains of SA, LBG 
by hydrogen bonding54. However it was found that 2% of glycerin gives the best 
plasticizer effect for KF loaded film. 
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Moisture uptake 
 Low moisture uptake was found in films with less percent of plasticizer, after 
stored in the above conditions. Films with low percent of plasticizer showed a lower 
capacity to absorb water compared to those with plasticizer. As the ratio of plasticizer 
and RH increases, moisture uptake was increased. This effect was more pronounced on 
films containing more amount of plasticizer and more amount of plasticizer showed an 
significant increases in moisture up take at increased RH55  
 
a. Uniformity of weight 
 Three different films of the individual batch are weighed and the average weight 
was calculated. The dried films were weighed on digital balance. The films exhibited 
uniform weight. The data of the individual weights are shown in the Table 7. 
Table 7. Uniformity of weight of Ketoprofen films (2.5 mg/cm2) 
 
Sl.N
o. 
 
Formulation 
code 
Weight of the patch in mg Mean ± S.D* 
Trial I Trial 
II 
Trial III 
1. F1 164 166 169 166.33±2.08 
2. F2 167 171 170 169.67± 1.53 
3. F3 184 187 182 184.67± 3.51 
4. F4 190 193 195 192.67± 1.15 
5. F5 199 196 195 196.33± 1.53 
6. F6 171 173 174 170.33 ±0.23 
7. F7 172 176 175 177.53 ±1.63 
 
 *Standard deviation, n=3 
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b. Uniformity of film thickness 
 The thickness of the films was measured at different points using screw gauge. 
The average of three readings were measured and presented in Table 8. 
Table 8. Uniformity of thickness of Ketoprofen film (2.5 mg/cm2) 
 
*Standard deviation, n=3 
c. Tensile strength 
 Tensile strength of the films was determined using Hounse field universal 
testing machine. The tensile strength of the films was taken directly from the dial 
reading in Newton’s. The films have shown reasonable tensile strength and moderate 
percentage elongation. The tensile strength increased whereas percentage elongation 
decreases. The data is shown in the Table 9. 
 
 
Sl.No. Formulation 
code 
Thickness of the patch in 
mm 
Mean±S.D* 
Trial 
I 
Trial 
II 
Trial III 
1. F1 0.11 0.13 .16 0.13±0.02 
2. F2 0.12 0.15 0.15 0.13± 0.01 
3. F3 0.13 0.15 0.16 0.14± 0.01 
4. F4 0.15 0.13 0.15 0.14± 0.01 
5. F5 0.16 0.15 0.16 0.15± 0.01 
6. F6 0.17 0.14 0.18 0.16± 0.01 
7. F7 0.18 0.14 0.17 0.17± 0.01 
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d. Percentage elongation 
 Percentage elongation of films is gives information of how much a specimen can 
elongate before it breaks. It was carried out by Hounse field universal testing machine. 
The percentage elongation at break point is measured on scale and the data of the 
percentage elongation is presented in the Table 9. 
 
Table 9. Tensile strength and % elongation of Ketoprofen film(2.5 mg/cm2) 
 
Sl. No. Formulation code Tensile strength(N/mm2) Percentage elongation 
1. F1 2.43± 0.01 21.30± 0.63 
2. F2 2.53± 0.04 21.56± 0.23 
3. F3 2.67± 0.02 22.45± 0.31 
4. F4 2.86± 0.02 24.4±1 0.14 
5. F5 3.08± 0. 15 26.38± 0.28 
6. F6 3.20± 0.12 29.36± 0.13 
7. F7 3.27± 0.03 34.14± 0.21 
 
e. Folding endurance 
 The folding endurance was measured manually for the prepared films. A strip of 
film 2x2 cm was cut evenly and repeatedly folded at the same place till it broke. The 
number of times the film could be folded at the same place without breaking gave the 
exact value of folding endurance. The data were presented in the table 10. 
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Table 10. Folding endurance of Ketoprofen drug loaded film (2.5 mg/cm2) 
Sl. No. Formulation 
code 
Folding Endurance Mean ±  S.D* 
Trial 
I 
Trial 
II 
Trial 
III 
1. F1 246 236 235 237.33±  5.86 
2. F2 246 254 246 248.67±  7.02 
3. F3 264 265 272 268.67±  4.16 
4. F4 266 276 262 267.33±  5.03 
5. F5 273 271 271 268.33±  7.37 
6. F6 276 283 278 276.50±  6.37 
7. F7 277 273 271 274.01±  6.87 
 
*Standard deviation, n=3 
f. Percentage moisture absorption 
 The moisture absorption studies carried out at 80% relative humidity. All the 
films showed least percentage moisture absorption. The data of the same is presented in 
the Table 11 
g. Percentage moisture Loss 
 The moisture loss studies carried in a desiccator containing anhydrous calcium 
chloride. All the films showed least percentage moisture loss. The data of the same is 
given in the Table 11 
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Table 11. Data of percentage moisture absorption and moisture loss (2.5mg/cm2) 
 
Sl.No. Formulation code % Moisture Absorption 
Mean ± S.D* 
% Moisture Loss      
Mean ± S.D 
1. F1 1.61± 0.34 1.23± 0. 15 
2. F2 1.60± 0.42 1.06± 0.10 
3. F3 1.63± 0.64 0.98± 0.16 
4. F4 1.38± 0.41 0.91± 0.10 
5. F5 1.87± 0.38 0.82± 0.40 
6. F6 1.92± 0.26 0.87± 0.26 
7. F7 1.95± 0.29 0.85± 0.37 
*Standard deviation, n=3 
h. Drug content  
 
 The drug content was analyzed by spectrophotometrically at 260nm and the data 
is given in the Table 12. The formulations exhibited uniform drug content and minimum 
batch variability. 
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Table 12. Drug content uniformity and percentage of drug content (2.5 mg/cm2) 
 
Sl.No. Formulation 
code 
Drug content in 
mg 
% of drug 
content 
1. F1 2.37 95.53 
2. F2 2.40 96.16 
3. F3 2.48 98.52 
4. F4 2.42 96.62 
5. F5 2.41 95.78 
6. F6 2.38 94.14 
7. F7 2.40 95.12 
 
i. Scanning Electron Microscopy (SEM) 
 
 The surface morphology of this film was observed using SEM as shown in F.5.4 
which indicates that the formulated film has smooth uniform surface. 
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Figure 5.4: Scanning electron microscopy of Ketoprofen films 
 
j. Stability Studies 
 Stability studies of KF loaded transdermal films were carried out to determine 
the amount of drug content as presented films and also determine the physical stability 
of the film given in table.13. 
Table 13. Stability studies of F3 formulation. 
 
Sampling 
Intervals in days 
Drug content 
250C/60% HR 
Drug Content 
300C/65% HR 
Drug content 
400C/75% HR 
15 98.46 98.28 98.18 
45 98.34 98.22 98.10 
60 98.21 98.12 98.10 
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k. Diffusion Study 
 
 The diffusion carried out for all the formulations to study for their in vitro drug 
diffusion. The kinetics of drug diffusion profiles was found out by using plotting 
different graphical models. All the profiles were presented in the respective table 14 to 
20. 
 
Table 14. In vitro Diffusion profile of Ketoprofen TDDS Formulation F1 (2.5 
mg/cm2) 
 
Times 
(hrs) 
√T LogT %Cumulative 
Drug released 
Log %Cum 
Drug 
released 
%Cum 
Drug 
Retained 
Log %Cum 
drug 
Retained 
0 0 0 0 0 0 0 
1 1.000 0.000 13.74 1.138 86.30 1.936 
2 1.125 0.085 16.95 1.230 83.10 1.918 
3 1.634 0.214 22.34 1.346 77.65 1.892 
4 1.900 0.280 28.84 1.460 72.12 1.57 
5 2.149 0.372 35.66 1.560 65.12 1.810 
6 2.800 0.423 43.02 1.64 57.14 1.760 
7 3.400 0.486 48.90 1.702 52.04 1.710 
8 3.366 0.518 55.86 1.782 45.28 1.648 
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Table 15. In vitro diffusion profile of Ketoprofen TDDS Formulation F2(2.5 
mg/cm2) 
 
Time(hrs) √T Log T    % 
Cumulative 
Drug 
Released 
 
Log 
%Cum 
  Drug 
 Released 
% 
Cumulative 
Drug 
Retained 
 
Log 
%Cum 
  Drug 
Retained 
 
0 0 0 0 0 0 0 
1 1.000 0.000 14.34 1.156 85.66 1.938 
2 1.214 0.084 
 
20.22 1.305 79.78 1.901 
3 1.632 0.212 
 
24.48 1.388 75.72 1.878 
4 1.900 0.278 
 
32.34 1.509 67.66 1.830 
6 2.149 0.370 
 
37.82 1.577 62.18 1.773 
8 2.728 0. 434 
 
40.62 1.669 59.38 1.770 
10 3.062 0.485 
 
51.20 1.708 49.80 1.679 
12 3.364 0.518 
 
58.24 1.720 47.76 1.620 
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Table 16. In vitro diffusion profile of Ketoprofen TDDS Formulation F3 (2.5 
mg/cm2) 
 
Time(hrs) √T Log T    % 
Cumulative 
Drug 
Released 
 
Log 
%Cum  
Drug 
Released 
% 
Cumulative 
Drug 
Retained 
 
Log 
%Cum  
Drug 
Retained 
 
0 0 0 0 0 0 0 
1 1.000 0.000 15.22 1.182 84.78 1.928 
2 1.214 0.084 
 
22.34 1.349 77.66 1.890 
3 1.632 0.212 
 
30.14 1.479 69.86 1.844 
4 1.900 0.278 
 
40.82 1.611 59.18 1.772 
6 2.149 0.370 
 
47.94 1.681 52.06 1.717 
8 2.728 0. 434 
 
53.12 1.725 46.88 1.671 
10 3.062 0.485 
 
63.72 1.804 36.28 1.560 
12 3.364 0.518 
 
70.28 1.847 29.72 1.473 
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Table 17. In vitro diffusion profile of Ketoprofen TDDS Formulation F4 (2.5 
mg/cm2) 
 
Time(hrs) √T Log T    % 
Cumulative 
Drug 
Released 
 
Log 
%Cum  
Drug 
Released 
% 
Cumulative 
Drug 
Retained 
 
Log 
%Cum  
Drug 
Retained 
 
0 0 0 0 0 0 0 
1 1.000 0.000 14.28 1.155 85.72 1.933 
2 1.214 0.084 
 
20.86 1.319 79.14 1.898 
3 1.632 0.212 
 
28.74 1.458 71.26 1.853 
4 1.900 0.278 
 
38.48 1.585 61.52 1.789 
6 2.149 0.370 
 
40.94 1.612 59.06 1.771 
8 2.728 0. 434 
 
41.8 1.621 58.20 1.764 
10 3.062 0.485 
 
42.70 1.630 57.20 1.758 
12 3.364 0.518 
 
50.66 1.704 49.34 1.693 
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Table 18. In vitro diffusion profile of Ketoprofen TDDS Formulation F5 (2.5 
mg/cm2) 
 
Time(hrs) √T Log T    % 
Cumulative 
Drug 
Released 
 
Log 
%Cum  
Drug 
Released 
% 
Cumulative 
Drug 
Retained 
 
Log 
%Cum  
Drug 
Retained 
 
0 0 0 0 0 0 0 
1 1.000 0.000 14.86 1.172 85.14 1.930 
2 1.214 0.084 
 
21.72 1.336 78.28 1.894 
3 1.632 0.212 
 
29.84 1.478 70.16 1.846 
4 1.900 0.278 
 
40.12 1.603 59.88 1.777 
6 2.149 0.370 
 
42.16 1.624 57.16 1.752 
8 2.728 0. 434 
 
50.84 1.703 49.16 1.691 
10 3.062 0.485 
 
52.86 1.723 47.14 1.673 
12 3.364 0.518 
 
56.88 1.754 43.12 1.634 
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Table 19. In vitro diffusion profile of Ketoprofen TDDS Formulation F6 (2.5 
mg/cm2) 
 
Time(hrs) √T Log T    % 
Cumulative 
Drug 
Released 
 
Log 
%Cum  
Drug 
Released 
% 
Cumulative 
Drug 
Retained 
 
Log 
%Cum  
Drug 
Retained 
 
0 0 0 0 0 0 0 
1 1.000 0.000 11.34 1.054 88.66 1.940 
2 1.214 0.084 
 
14.15 1.150 85.58 1.930 
3 1.632 0.212 
 
19.86 1.297 80.14 1.903 
4 1.900 0.278 
 
26.32 1.420 73.38 1.867 
6 2.149 0.370 
 
33.12 1.520 66.88 1.925 
8 2.728 0. 434 
 
40.82 1.610 59.18 1.772 
10 3.062 0.485 
 
46.54 1.667 53.47 1.728 
12 3.364 0.518 
 
53.12 1.725 46.88 1.670 
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Table 20. In vitro diffusion profile of Ketoprofen TDDS Formulation F7 (2.5 
mg/cm2) 
 
 
Time(hrs) √T Log T    % 
Cumulative 
Drug 
Released 
 
Log 
%Cum  
Drug 
Released 
% 
Cumulative 
Drug 
Retained 
 
Log 
%Cum  
Drug 
Retained 
 
0 0 0 0 0 0 0 
1 1.000 0.000 10.12 1.005 89.88 1.953 
2 1.214 0.084 
 
13.12 1.117 86.88 1.936 
3 1.632 0.212 
 
18.18 1.259 81.82 1.912 
4 1.900 0.278 
 
25.19 1.401 74.81 1.873 
6 2.149 0.370 
 
32.46 1.511 67.54 1.829 
8 2.728 0. 434 
 
39.12 1.592 60.88 1.784 
10 3.062 0.485 
 
45.35 1.656 54.65 1.737 
12 3.364 0.518 
 
32.10 1.716 47.90 1.860 
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Figure 5.5: Comparative in vitro diffusion profiles of Ketoprofen TDDS according 
to Zero order kinetics 
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Figure 5.6: Comparative in vitro diffusion profiles of Ketoprofen TDDS                   
according to First order kinetics 
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Figure 5.7: Comparative in vitro release profiles of Ketoprofen TDDS according to 
Higuchi matrix 
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Figure 5.8: Comparative in vitro diffusion profiles of Ketoprofen TDDS                     
according to Peppas kinetics 
 
Table 21. Results of Model Fitting of Ketoprofen TDDS 
 
Formulation Zero order First order Higuchi 
Matrix 
Peppas 
Plot 
‘n’ values 
F1 0.9590 0.9976 0.9897 0.9969 0.6111 
F2 0.9427 0.9935 0.9924 0.9944 0.6013 
F3 0.9492 0.9911 0.9871 0.9912 0.6360 
F4 0.9447 0.9674 0.9876 0.9899 0.6278 
F5 0.9417 0.9654 0.9878 0.9896 0.6211 
F6 0.9413 0.9632 0.9853 0.9886 0.6201 
F7 0.9401 0.9618 0.9832 0.9879 0.6203 
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l. The comparative skin permeation parameters of different formulations 
obtained were shown in Table no.22. 
 
Table 22: In vitro skin Permeability parameters of different formulations 
 
Formulation Menthol (%) Jss (mg/cm2/h) ± Permeability 
coefficient 
(Kp) 
Er 
Gel Control - 0.029±0.034 0.120±0.086 1.0±0.12 
F1 1.0 0.160±0.013 0.151±0.067 5.3±0.14 
F2 2.0 0.231±0.024 0.210±0.054 7.7±0.16 
F3 3.0 0.250±0.013 0.219±0.32 8.3±0.21 
F4 3.5 0.226±0.022 0.210±0.053 7.5±0.35 
F5 4.0 0.208±0.053 0.190±0.066 6.9±0.10 
F6 4.5 0.196±0.042 0.180±0.021 6.5±0.09 
F7 5.0 0.170±0.011 0.161±0.010 5.6±0.19 
 
m. Anti-inflammatory activity 
 
 The anti-inflammatory efficacy of Ketoprofen films in mice paw oedema 
induced by the Carrageenan was tested and the results were compared with that of the 
conventional gel without menthol. The paw oedema volume was measured for 12h 
period, after the Carrageenan injection. The inhibition of oedema was observed and the 
comparative reduction in paw oedema volume, according to the mode of administration 
was recorded with respect to the control group. A significant inhibition of inflammation 
was found with conventional gel formulation (without menthol) presented in figure 9. 
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Figure 5.9: Comparative inhibition of inflammation from formulations and gel. 
 
6. DISCUSSION 
6.1 PREFORMULATION STUDIES 
 Preformulation studies are necessary to understand the physicochemical 
properties of the drug and the compatibility of the other excipients used in the 
formulation. The results of the various 
Preformulation characterizations are discussed below. 
A. Determination of melting point 
 Melting point of Ketoprofen was found to be 93.50C 
B. Solubility studies 
 Ketoprofen is freely soluble in soluble in phosphate buffer pH 7.4, ethyl alcohol, 
methyl alcohol, chloroform, acetone, dichloro methane, and ether insoluble in water. 
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C. Determination of partition co-efficient 
 The value of partition co-efficient obtained indicates that the drug possesses 
sufficient lipophilicity, which fulfill the requirements of formulating the selected drug 
into a transdermal film. The biphasic nature of drug mimics the biphasic nature of skin, 
thus ensuring easy penetration through the skin. 
D. Development of calibration curve for Ketoprofen ( λmax) 
The absorption maximum (λmax) was obtained as 260nm. This implies the purity of the 
sample drug ketoprofen. 
E. FT-IR study 
 FT-IR study was employed to ascertain the compatibility of the Ketoprofen with 
the LBG and SA. Both the spectra were compared for confirmation of common peaks. 
Specific peaks of ketoprofen and ketoprofen films showed no significant variation in 
height, intensity and positions of peaks. This confirms that there is no chemical 
interaction between drug and polymers. 
F. Differential Scanning Calorimetry (DSC) 
 DSC studies were carried out on pure drug and drug loaded films. It was 
understood that the drug and the excipients used were compatible. Also indicated, that 
the drug is distributed uniformly in the films without any degradation. 
6.2 EVALUATION OF TRANSDERMAL FILMS  
A. Determination of film forming character 
 The films prepared using 40.5 % of LBG, 52.0% SA, 2 % Plasticizer and 3.0% 
W/W of menthol forms smooth, flexible, transparent and having sufficient mechanical 
strength. 
 
B. Evaluation of drug loaded films 
 The drug loaded films were formulated using polymer, glycerin used as 
plasticizer, and menthol as permeation enhancer. The prepared films were evaluated for 
its physicochemical and mechanical properties and the same were discussed 
individually. 
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a. Uniformity of weight 
 Three different dried films of the individual batch were weighed using digital 
balance and the average weight was calculated. The films exhibited uniform weight and 
there was no deviation in the weight of any formulation. 
b. Uniformity of film thickness 
 The thickness of the films was measured at different points using screw gauge. 
The films showed uniformity in their thickness. 
c. Tensile strength 
 Tensile strength of the films was determined using Hounse field universal 
testing machine. The tensile strength increased where as percentage elongation 
decreases with increasing the concentration of Glycerin. The tensile strength results 
obtained in formulations indicate the risk of film cracking. The films have shown 
reasonable tensile strength and no sign of cracking in the films observed, which may be 
attributed to addition of plasticizer. 
d. Percentage elongation 
 The films have shown moderate percentage elongation and exhibited 
satisfactory elongation. The tensile strength increased whereas percentage elongation 
decreases with increasing the concentration of LBG and glycerin. 
e. Folding endurance 
 The folding endurance was determined manually by repeatedly folding the film 
at same place until it broke. The formulated film F3 exhibited optimal folding 
endurance without any batch variation. 
f. Percentage moisture absorption 
 The moisture absorption studies carried out at 80 % relative humidity. All the 
films showed least percentage moisture absorption. This shows that the film protects the 
materials from microbial contamination and bulkiness of the films. Low moisture 
absorption was found in films with less percent of plasticizer. 
j. Moisture loss 
 Moisture loss was carried out in desiccators containing anhydrous calcium 
chloride .The films should containing least percentage of moisture loss 
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h. Drug content 
 The drug content was analyzed by spectrophotometrically at 260nm. All the 
formulations determine fairly uniform drug content ranging from 2.37to2.48 mg/cm2. 
The drug content analysis of the formulations have showed that the process employed to 
prepare films in this study was capable of giving films with uniform drug content and 
minimum batch variability. 
i. Scanning Electron Microscopy (SEM) 
 The surface morphology of this film was observed using scanning electron 
microscopy and which indicates that the formulated film has smooth surface with 
elegant appearance and good physical appearance. It shows that the drug is uniformly 
distributed throughout the film. Flatness of the films was observed better when the 
amount of LBG was more than 52 .5% in films. The viscosity of the films was found in 
the range of 392.13 to 403.45 Cp and increased concentrations of SA more viscosity. 
j. Stability studies 
 There was no significant change in the physical property and drug content 
during the study period. 
k. Diffusion Study 
 The matrix diffusion controlled transdermal drug delivery system of ketoprofen 
was studied for their in vitro drug diffusion to observe the kinetics of drug diffusion 
from the formulations. The in vitro drug release kinetics of the prepared ketoprofen 
films was found out by using plotting different graphical models. Diffusion studies were 
carried out in an open glass diffusion tube, using hydrated cellophane as a diffusion 
membrane.  
 
 Diffusion studies for all thefilms were carried out for 8 h in normal saline. From 
the diffusion studies, it was observed that, there was no significant diffusion of drug 
from KF films at gastric pH. At the end of 8th h, drug diffuses from formulation F3 
(70.28) was maximum than F1 (55.74%), F2 (58.24%), F4 (50.66%), F5(56.88%), F6 
(53.12%), F7 (52.10%) and conventional gel (88.3%) shown in Fig5.5 From the figure, 
it was clear that maximum amount of KF was diffuses from the formulation (F3). From 
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the above results, it can be concluded that drug diffusion from the films was controlled 
due to increased amounts of LBG showed higher swellability of the film and leached 
plasticizer from the film could reduce tortuosity of aqueous pore channels of the films, 
respectively56. In order to understand mechanism of drug release, in vitro release data 
were treated to kinetic models and linearity was observed with respect to Higuchi 
equation. The correlation coefficient obtained from Higuchi plot was found to be in the 
range of 0.9832 to 0.9924. This indicates that mechanism of drug release was diffusion 
type. As indicated by higher R2 values, the drug release from all formulations follows 
first order release and Higuchi model. Since it was confirmed as Higuchi model, the 
diffusion mechanism was swelling and diffusion controlled. The Peppas model is 
widely used to confirm whether the release mechanism is fickian diffusion, non-fickian 
diffusion or zero order. ‘n’ value could be used to characterize different release 
mechanisms. 
Peppas-korsmeyer equation is given as:- 
% R = K tn 
Or Log % R = log K + n log t 
Where, R = drug release, n = slope,k = constant, t = time. 
‘n’ Mechanism 
0.5 Fickian Diffusion (Higuchi matrix) 
0.5 < n < 1 Non Fickian Diffusion 
1 Case II Transport (Zero order) 
  
 The ‘n’ values for all formulations were found to be more than 0.50. Hence, this 
indicates that the diffusion approximates Fickian diffusion mechanism. 
L. In vitro skin permeation studies 
 In vitro skin permeation studies were performed to compare the release of drug 
from 7 different film formulations (F3‐ F7) and conventional gel, all having the same 
quantity of ( 2.5% w/w )KF. As expected the flux of KF from films was found 
significantly higher (P <0.05) than the flux of KF from conventional gel presented in 
Table.22. In vitro skin permeation was highest and lowest in formulation F3 and F7 
respectively, The formulations F4 showed an intermediate skin permeation profile. 
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 Increasing the concentration (3 to 5% w/w) of penetration enhancer showed a 
significant difference P < 0.05) in the flux of KF. The highest flux and enhancement 
ratio for KF from the film (F3) containing menthol was found to be 0.250 ± 0.13 
mg/cm2/h & 8.3 mg/cm2/h respectively. The skin permeation profile of film F3 was 
significantly different (P <0.05), when compared with that of F4. Thus, menthol is 
expected to be a moderate skin permeation enhancer. In contrast, menthol enhanced the 
skin permeation of the drug by increasing both the skin concentration and the diffusion 
rate in skin because menthol contains functional group of hydrogen bonding. KF is 
lipophillic drug and menthol is a lipophillic terpene found to be more effective because 
menthol found to enhance the penetration of drug by both lipid and pore pathway 57, 58. 
Increase in the concentration of penetration enhancer from 1% wt/wt to 3% even after 
increasing the penetration enhancer from 4% w/wt to 5% and plasticizer from 2.5% to 
4% w/w in formulation F4 and F7 showed decreased enhancement ratio. Because 
increased ratio of LBG/SA in the films showed higher swellability of the film, 
plasticizer leaches from the film could reduce tortuosity of aqueous pore channels of the 
films. So that delivery of drug at a controlled rate across intact skin to achieve a 
therapeutically effective drug level for a longer duration of time from transdermal films. 
When enhancement ratio <1.0 indicates that enhancer 
has no permeation enhancing activity.  
m. Anti inflammatory studies 
 Based on higher drug permeation, formulation F3 was selected for the in vivo 
anti inflammatory effects and compare with conventional gel. A significant inhibition (p 
< 0.05) of inflammation was found with the film formulation F3 containing 3 % w/w 
menthol in comparison to the conventional gel without menthol. The percent inhibition 
value after 24h was found to be more F3 as compared to gel formulation without 
penetration enhancer and the difference between formulation F3 and conventional gel 
percent inhibition was significant (p < 0.05). The enhanced anti inflammatory effects of 
formulation F3 could be due to the enhanced permeation of KF though the skin. The 
anti inflammatory studies was performed to confirm the safety of optimized formulation 
F3. Literature survey reported that a value between 0 to 9 indicates that the applied 
formulation is generally not an irritant to human skin. The enhancement ratio was found 
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to formulation F3 8.3. From this it was concluded that optimized formulation F3 was 
safe to be used for transdermal drug delivery. Based on higher drug permeation and 
lower Viscosity formulation F3 was selected for the study of anti inflammatory effect. 
The anti inflammatory was evaluated by reported carragenean induced hind paw 
oedema method on rats and the inhibition of Inflammation was compared with 
conventional gel without penetration enhancer. The conventional gel shows less 
inhibition and significant inhibition (P<0.5), of inflammation was found with other 
formulation in comparison showed in figure 9. The in vivo results found to be 
correlation with in vitro permeation results. The enhanced anti inflammatory effects 
could be due to the enhanced permeation through the skin. 
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7. SUMMARY 
 
 The principle of transdermal drug delivery systems is to deliver the drug across 
epidermis to achieve systemic effect over a prolonged period of time. Because of these 
attributes, transdermal drug delivery systems offer many advantages such as reduced 
side effects, improved patient compliance, elimination of first-pass metabolism and 
sustained drug delivery. Ketoprofen is one of the important NSAID that have been 
widely used in the treatment of rheumatoid arthritis and related conditions. In the 
present study was aimed to formulate and evaluate the Transdermal drug delivery 
system of Ketoprofen. Ketoprofen selected as the drug candidate for the development of 
transdermal films, because of its low molecular weight, lipophilicity, considerable first-
pass metabolism in liver, shorter plasma half life and excellent permeability through 
skin. Locust been gum and sodium alginate was used as polymers for the fabrication of 
matrix film because of its excellent film forming property. Glycerin was used as 
plasticizer to maintain the flexibility of the film and study the effect of drug diffusion 
property. Menthol was used as permeation enhancer to study the permeability effect. 
The method of casting the film on the fabricated mould was found to be satisfactory. 
The films were prepared with polymer alone were found to be brittle. 5 % w/w 
plasticizer glycerin was used to prevent embrittlement andwhich gave thin, flexible, 
smooth and transparent films. Physicochemical evaluation carried out for all the 
formulations. Solubility study was conducted to determine the sink condition property 
of the media phosphate buffer (pH 7.4) in diffusion studies. Phosphate buffer dissolves 
sufficient amount of drug and shows necessary character to maintain sink condition. 
The drug determines the sharp melting point at 93.5 C. The partition co-efficient values 
indicate that the drug possesses sufficient lipophilicity and fulfills the requirements of 
formulating the selected drug. FT-IR spectroscopy was used to study the drug-
excipients interactions and it shows no physical and chemical interaction between drug 
and polymer. The DSC studies were carried out to understand the drug and the 
excipients used were compatible. It was indicated, that the drug is distributed in the 
films without any degradation. The SEM study indicates that the formulated film has 
smooth uniform surface and shows that the drug is uniformly distributed throughout the 
film. The drug loaded film exhibits satisfactory results of uniformity of weight, 
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uniformity of thickness, tensile strength and percentage of elongation. The films were 
exhibited optimal folding endurance without any batch variation. It was observed that 
films were having low average of % moisture absorption and moisture loss is one of the 
physicochemical characteristics in the formulation of transdermal films. The films 
shows small amount of moisture absorption. This result favours the stability and 
compatibility of the formulation in a high humid environment. The formulations 
determine fairly uniform drug content ranging from 95.5 to 98.5% with minimum of 
batch variability. The diffusion study of the formulation was essential for ensuring a 
sustained release and reproducibility of the rate and the duration of drug release. Drug 
diffusion study was conducted using Franz diffusion cell and synthetic release 
membrane. All the formulations were shown satisfactory cumulative percentage of drug 
release. According to the cumulative percentage of drug release profiles it was 
understood that the cumulative percentage drug release increased with increase in the 
plasticizer concentration. It can be stated that there is a significant variation in the 
cumulative percentage of drug release between F1 to F7. But there was no significant 
variation of cumulative percentage of drug release between F3 to F5. Hence the 
formulation F3 was found to be ideal formulation for satisfactory drug diffuse. The 
diffusion values revealed that the diffusion kinetic model follows first order, Higuchi, 
and Zero order. Based on the R2 value, it was confirmed as Higuchi model, the release 
mechanism was swelling and diffusion controlled. According to Peppas diffusion 
exponent of release profiles the ‘n’ values lies from 0.6 to 0.63, which indicates non-
fickian transport diffusion. A primary skin irritation test studies was conducted on 
Albino rabbit skin and there was no signs of erythema or edema. It indicates that the 
transdermal films are safe for use. The efficacy of the anti-inflammatory activity was 
carried out by Carrageenan induced inflammation edema in mice. The formulation F3 
showed a comparative reduction in the edema volume with respect to the oral solution 
of Ketoprofen. It revealed that the formulation F3 can able to produce maximum 
percutaneous penetration in a sustained release manner. 
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8. CONCLUSION 
 
 On the basis of good mechanical properties, better compatibility and stability of 
drug with polymer, highest drug permeation, we selected film formulation F3 (3% 
Menthol) for use in In vivo studies. The in vivo studies revealed a significant increase in 
anti inflammatory effects as compared with conventional gel without menthol. From in 
vitro and in vivo data it can be concluded that the developed film formulation F3 have 
great potential for transdermal drug delivery. Developed film formulation F3 has the 
best effective combination of polymer to achieve therapeutic plasma concentration. But 
additional experiments should be carried out before the film formulations are used on 
humans. 
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